Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

ABSTRACT: Conventional assays evaluating antitumor activity of immune effector cells have limitations that preclude their high-throughput application. We adapted the recently developed Compartment-Specific Bioluminescence Imaging (CS-BLI) technique to perform high-throughput quantification of innate antitumor activity and to show how pharmacologic agents (eg, lenalidomide, pomalidomide, bortezomib, and dexamethasone) and autologous BM stromal cells modulate that activity. CS-BLI-based screening allowed us to identify agents that enhance or inhibit innate antitumor cytotoxicity. Specifically, we identified compounds that stimulate immune effector cells against some tumor targets but suppressed their activity against other tumor cells. CS-BLI offers rapid, simplified, and specific evaluation of multip

SUBMITTER: McMillin DW 

PROVIDER: S-EPMC3325048 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature